



28th July, 2025

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Appointment of Aman Mehta as Managing Director of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform that the shareholders at 52nd Annual General Meeting held today, have approved the appointment of Aman Mehta (holding DIN: 08174906) as Managing Director and Whole-time Key Managerial Personnel of the Company for the period of 5 years w.e.f. 1st August, 2025 by pre-closing his current appointment as “Whole-time Director”.

Further, we would like to inform that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

The details as required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 is enclosed as **Annexure-A**.

The above is for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl : A/a

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

Annexure-A

| Particulars | Details |
|---|--|
| Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise | Appointment of Aman Mehta (holding DIN: 08174906) as Managing Director and Whole-time Key Managerial Personnel of the Company for the period of 5 years w.e.f. 1 st August, 2025 by pre-closing his current appointment as “Whole-time Director” |
| Date of appointment / reappointment / cessation (as applicable) & term of appointment | Date of Appointment: 1 st August, 2025 Term of appointment: 5 years w.e.f. 1 st August, 2025. |
| Brief Profile (In case of appointment) | <p>Aman Mehta holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York. He brings with him a dynamic blend of academic excellence and practical leadership experience across diverse business sectors.</p> <p>During his 10+ year tenure with Torrent, Aman has held key leadership positions in both the Power and Pharma verticals of the Group. As an Executive Director at Pharma, Aman has primarily been involved in the India business, Torrent’s largest revenue contributor. He played an instrumental role in the seamless integration of the Unichem acquisition and the strategic identification and integration of Curatio Healthcare, both of which delivered substantial value and synergies to the Company.</p> <p>Since his appointment as Whole-time Director, Aman has continued to make a significant impact on the Company’s growth and transformation journey. His contributions include:</p> <ul style="list-style-type: none"> • Leading several organic growth initiatives that have begun delivering measurable market share expansion. His efforts have focused on the launch of new products and broadening market presence in focus therapies. • Driving strategic evaluation and execution of inorganic opportunities, with a strong emphasis on long-term value creation for the India business. |

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

| | |
|--|---|
| | <ul style="list-style-type: none"> • Bringing a renewed focus on innovation, empowerment, and sustainability by fostering a high-performance culture rooted in the Company's core values and philosophies. • His notable contribution to long term sustainable growth for India business are as under: <ul style="list-style-type: none"> ○ Driving field force expansion from 3,600 MRs in 2022 to 6,400 MRs in FY2025, with year on year improvement in productivity and market share ○ Turnaround in cardiac portfolio, Torrent's largest revenue contributor which was earlier marred with legacy portfolio issues ○ Increase in rank in Diabetes (OAD) TA from 11th to 6th, with an ambition to reach the top 3 in the near future ○ Portfolio revamp with addition of complex products with large addressable markets in India, with a goal to in first wave of launches ○ Launching the Consumer Health Division with a focus on 4 key brands that has delivered meaningful growth acceleration ○ New launch excellence across TAs, achieving top 3 market share ranks in most new launches in the recent past ○ In-licensing key products as growth levers (empagliflozin, saroglitazar etc.) ○ Turnaround of mature Unichem portfolio to double digit growth and delivering industry leading margins ○ Acceleration of Curatio portfolio growth with emphasis on commercial excellence and product innovation <p>In addition to these contributions, Aman has taken charge of the Research & Development and Operations (Supply chain & procurement included) functions. Under his leadership:</p> <ul style="list-style-type: none"> • R&D has witnessed a sharper alignment with business strategy, emphasizing differentiated product development and accelerated timelines for critical projects. • Operational excellence initiatives have been introduced to enhance productivity and cost efficiency across |
|--|---|

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

 Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
 www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

| | |
|---|---|
| | <p>manufacturing and supply chain processes, resulting in tangible improvements in margins and service levels.</p> <p>Aman's contributions as Whole-time Director have been substantial in advancing the Company to its next phase of growth. Through a combination of strategic foresight, operational rigor, and people-centric leadership, he continues to play a key role in transforming the Company into a more agile, innovative, and globally competitive organization.</p> |
| <p>Disclosure of relationships between directors (in case of appointment of Director)</p> | <p>He is relative of Samir Mehta, Executive Chairman of the Company.</p> |

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com